Sickle Cell NIPT: Non-Invasive Prenatal Screening for Your Unborn Baby, Now Available Across Africa
- Greenplace Healthcare
- Jul 5
- 5 min read
Contact us:
Whatsapp: +447585610211
Global Line: +442081500059
Sickle cell disease is not a distant statistic for African families — it is a lived reality. In Nigeria alone, close to 1 in 4 people carry the sickle cell trait, which means for millions of couples, the question of whether their baby will inherit sickle cell disease is not hypothetical. It is personal, and it is urgent.
At Greenplace Healthcare, in partnership with London Diagnostics Clinic (LDC), we are proud to bring Sickle Cell NIPT — a safe, non-invasive prenatal test for sickle cell disease — to expectant parents across the African continent. Whether you are in Lagos, Accra, Nairobi, Kampala, or anywhere in between, you no longer have to travel abroad or wait until birth to understand your baby's sickle cell status.
Understanding Sickle Cell Disease
Sickle cell disease is an inherited blood disorder. Instead of the round, flexible red blood cells that flow easily through the body, people with sickle cell disease have red blood cells shaped like a sickle, or the letter "C." These misshapen cells are rigid and can block blood flow, leading to pain crises, infections, and in serious cases, organ damage and stroke. Because the condition can also reduce the number of healthy red blood cells available to carry oxygen, it frequently leads to anaemia as well.
Sickle cell disease is passed down genetically, through genes inherited from both parents. Every person carries two copies of the relevant gene — one from each parent. This is what makes prenatal testing so important for couples who may be carriers.
How Sickle Cell Is Inherited
If a baby inherits the sickle cell gene change from both parents, the baby will have sickle cell disease (genotype SS).
If a baby inherits the gene change from only one parent, the baby will have sickle cell trait (genotype AS) — a carrier who does not have the disease itself and, in the vast majority of cases, will show no symptoms of it.
Sickle cell trait cannot turn into sickle cell disease later in life. The risk is only ever set at conception.
For couples where both partners carry the sickle cell trait (AS x AS), each pregnancy carries the following chances:
75% (3 in 4) chance the baby will not have sickle cell disease
50% (1 in 2) chance the baby will have sickle cell trait (a carrier, like the parents)
25% (1 in 4) chance the baby will have sickle cell disease
25% (1 in 4) chance the baby will have neither the disease nor the trait
If both partners already have sickle cell disease themselves (SS x SS), every child will be born with sickle cell disease.
Given these odds, any couple where one or both partners are known carriers (AS) or affected (SS) has a clear, practical reason to seek prenatal screening rather than wait and wonder.
What Is Sickle Cell NIPT?
Sickle Cell NIPT is a Non-Invasive Prenatal Test (NIPT) engineered specifically for high-prevalence settings and validated on African genotypes. It screens your unborn baby for the sickle cell mutation (HbS) from as early as 10 weeks of gestation.
Rather than requiring an invasive procedure such as amniocentesis or chorionic villus sampling — both of which carry a small but real risk to the pregnancy — Sickle Cell NIPT works by analysing tiny fragments of your baby's cell-free DNA (cfDNA) that circulate naturally in your bloodstream during pregnancy. The result: a single blood draw from the mother's arm can reveal both the mother's own carrier status and, if she is a carrier, her baby's inherited risk.
Who Should Choose Sickle Cell NIPT?
Couples where one or both partners are known carriers (AS) or affected (SS)
Pregnant women who want early, definitive insight into their baby's HbS risk so they can plan the rest of their antenatal journey with confidence
Families with a history of sickle cell disease or sickle cell trait who want clarity rather than uncertainty
What Your Result Will Tell You
Sickle Cell NIPT gives you a clear, actionable risk classification rather than a vague probability:
Low-Risk for Fetal HbSS — the baby is unaffected or, at most, a carrier
High-Risk for Fetal HbSS — the baby is likely affected with sickle cell disease
Results carry 95–99% sensitivity and 95–100% specificity for fetal genotype differentiation in carrier mothers, giving families a level of accuracy that supports real, informed decision-making rather than guesswork.
Why Choose a Non-Invasive Test?
The appeal of NIPT lies in the word "non-invasive." A simple maternal blood draw carries none of the miscarriage risk associated with amniocentesis or CVS, yet it can deliver comparably reliable insight into your baby's genetic risk. For parents who are already carrying the emotional weight of a possible sickle cell diagnosis, removing the added anxiety of an invasive procedure matters.
Every Sickle Cell NIPT sample is processed in an ISO 15189–accredited genetics laboratory, with rigorous internal and external quality checks and expert bioinformatics analysis behind every report. You also receive clinical interpretation and next-step guidance with your result, not just a number on a page.
We always encourage parents to discuss their results with a genetic counsellor, who can help you understand what your family's genetic picture means for your health and your baby's — and what your options look like from there.
One Test, Available Across Africa
This is where our partnership comes in. Greenplace Healthcare, working alongside London Diagnostics Clinic, has built the infrastructure to bring Sickle Cell NIPT to expectant parents wherever they are on the continent.
Head Office — London, UK: our clinical and diagnostics partner, London Diagnostics Clinic, is headquartered in London, anchoring the clinical governance and laboratory standards behind every test.
Nigeria Branch: our Lagos-based team means African families don't have to look abroad for world-class prenatal screening — it's already here, close to home.
Continent-Wide Delivery: through our established logistics network, we can arrange Sickle Cell NIPT sample collection and delivery for expectant parents anywhere across Africa — not just in Nigeria and the UK.
Whether you're in a major city or a location further from a large diagnostics lab, our team can coordinate the collection kit, sample logistics, and reporting process so that distance is never the reason you go without answers.
How to Get Started
Getting your Sickle Cell NIPT arranged is simple. Reach out to our team and we'll guide you through the entire process, from booking your sample collection to explaining your results when they arrive.
Whatsapp: +447585610211
Global Line: +442081500059
Our team will talk you through eligibility, collection logistics wherever you are in Africa, and what to expect once your sample reaches our partner laboratory.
Frequently Asked Questions
What is Sickle Cell NIPT? Sickle Cell NIPT is a non-invasive prenatal blood test that screens for the sickle cell mutation (HbS) in your unborn baby, from as early as 10 weeks of pregnancy, using a simple maternal blood sample.
How early can I take the Sickle Cell NIPT? The test can be performed from 10 weeks of gestation.
Is Sickle Cell NIPT safe for my pregnancy? Yes. Because it only requires a blood sample from the mother's arm, there is no risk to the pregnancy, unlike invasive procedures such as amniocentesis.
Who should consider Sickle Cell NIPT? Couples where one or both partners are known carriers (AS) of the sickle cell trait, or affected (SS) by sickle cell disease, and any pregnant woman who wants early clarity on her baby's sickle cell risk.
How accurate is the test? Sickle Cell NIPT offers 95–99% sensitivity and 95–100% specificity for fetal genotype differentiation in carrier mothers.
Where is Sickle Cell NIPT available? Our head office is in London, with a dedicated branch in Nigeria, and we can arrange sample collection and delivery for parents anywhere across Africa.
How do I book a test? Contact our team by email, WhatsApp, or phone call, and we'll arrange everything from sample collection to result delivery.
Contact us:
Whatsapp: +447585610211
Global Line: +442081500059
These methods provide contextual spatial information across tumor tissue, circulating tumor cells (CTCs), cell therapies and preclinical models to aid target validation, mechanism-of-action and translational decision making throughout drug development.